Skip to main content
S&P 5007,592.40-0.35%DOW52,297.09-0.36%NASDAQ25,366.09-0.39%BTC$69,200.00-5.06%ETH$1,956.85-3.16%GOLD$3,897.50+0.31%OIL$88.62-0.14%
Smart Investors Daily
SID Premium
MI

NASDAQ · MIST

Milestone Pharmaceuticals Inc.

Healthcare · Biotechnology

$0.66

Down-$0.01 (-1.06%)

Updated Nov 13, 2026, 12:40 PM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
252.53M
P/E ratio
-6.21
Dividend yield
0.00%
52-week range
$0.63 – $2.34
Volume
1.09M
Avg. volume
2.14M

Price performance · MIST

MIST price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 12, 2026

MIST closed at $0.66 after 21 trading sessions, down 17.53% for the selected period.

Last close
$0.66
Period change
-17.53%
Period low
$0.64
Period high
$0.79
Daily close
View OHLC price history
MIST OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 12, 2026$0.69$0.707$0.6425$0.65521.09M
Nov 11, 2026$0.6877$0.709$0.65$0.66226.45M
Nov 10, 2026$0.7299$0.76$0.6622$0.66221.68M
Nov 9, 2026$0.78$0.79$0.738$0.7382.63M
Nov 6, 2026$0.72$0.7699$0.7021$0.7628556.42K
Nov 5, 2026$0.7614$0.785$0.6752$0.69251.19M
Nov 4, 2026$0.7774$0.7999$0.75$0.7725696.02K
Nov 3, 2026$0.72$0.7661$0.72$0.7593566.03K
Nov 2, 2026$0.7708$0.7799$0.7202$0.7211748.84K
Oct 30, 2026$0.79$0.7997$0.7259$0.73730.16K
Oct 29, 2026$0.7574$0.8363$0.7484$0.7896796.93K
Oct 28, 2026$0.7032$0.7699$0.6879$0.7574832.65K
Oct 27, 2026$0.65$0.696$0.644$0.6912754.47K
Oct 26, 2026$0.65$0.6682$0.6307$0.6444802.49K
Oct 23, 2026$0.71$0.71$0.6338$0.64821.58M
Oct 22, 2026$0.69$0.739$0.69$0.7027621.34K
Oct 21, 2026$0.72$0.7279$0.695$0.6953673.28K
Oct 20, 2026$0.70$0.7449$0.70$0.7185502.31K
Oct 19, 2026$0.719$0.7399$0.6961$0.7001669.89K
Oct 16, 2026$0.80$0.80$0.704$0.7073980.76K
Oct 15, 2026$0.7862$0.7994$0.752$0.79451.04M

Latest MIST news

The latest Smart Investors Daily articles mentioning MIST.

Stock researchCompany · Overview

MIST research

Overview

Company profile and research snapshot.

Company profile

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$10.00
Implied upside
—
Analysts
—
MIST recent ratings
DateFirmRatingTarget
Sep 3, 2026HC Wainwright & Co.Buy—
Aug 20, 2026Cantor FitzgeraldOverweight—
May 14, 2026Wells FargoOverweight—
Jan 6, 2026HC Wainwright & Co.Buy—
Dec 16, 2025Wells FargoOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 4, 2026

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MONTREAL and CHARLOTTE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 33,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to the hiring of one new emplo

Yahoo · Nov 3, 2026

Milestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026

MONTREAL and CHARLOTTE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report its financial results for the third quarter ended September 30, 2026, and provide a business update before the market open. The announcement will be followed by a conference call and webcast for investors at 8:30 am ET. To access the l

Yahoo · Nov 2, 2026

New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation

MONTREAL and CHARLOTTE, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced new data showing that CARDAMYST® (etripamil) nasal spray converted approximately two-thirds of patients who experienced recurrent symptomatic paroxysmal supraventricular tachycardia (PSVT) after a prior catheter ablation to normal heart rhythm within 30 m

Yahoo · Oct 23, 2026

Milestone Pharmaceuticals (MIST) Stock Sees Fair Value Falls As Analysts Reset Cardamyst Expectations

The updated average fair value estimate for Milestone Pharmaceuticals has moved from US$6.60 to US$5.71, which is roughly a 13% reduction in the price target. Analysts link this shift to a more cautious stance on Cardamyst launch execution and the pace of payer coverage and prescriber expansion, even as some remain optimistic about the AFib RVR opportunity. Read on to see how this evolving narrative might shape the way you track Milestone Pharmaceuticals from here. Analyst Price Targets don't...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By